Coherus BioSciences Appoints Lee Healthcare Payment Expert


REDWOOD CITY, Calif., Feb. 07 10, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and senior healthcare executive Lee N. Newcomer, MD , to its Board of Directors as of February 2, 2022.

“We are delighted to welcome Dr. Newcomer to the Coherus Board of Directors. Lee has dedicated her career to improving cancer care by applying her expertise in clinical oncology, access and reimbursement. His unique understanding of the healthcare industry will help us accelerate our strategic evolution into a leading innovative immuno-oncology company,” said Denny Lanfear, CEO of Coherus.

Dr. Newcomer has spent most of his career at UnitedHealthcare, where he most recently served as Senior Vice President, Oncology and Genetics, focusing on improving the affordability and quality of cancer care. He joined UnitedHealthcare in 1991 as Medical Director. Previously, Dr. Newcomer was Medical Director of CIGNA Health Care of Kansas City and practiced oncology for nine years. Dr. Newcomer sits on the boards of Cellworks Group and Myriad Genetics. He earned a BS in Biology from Wesleyan University of Nebraska and an MD from the University of Nebraska-Omaha. Dr. Newcomer earned a master’s degree in health and healthcare administration and management from the University of Wisconsin-Madison.

Mr. Lanfear continued, “The market access strategy and its execution is critically important to the upcoming launch of YUSIMRY™ in the $18 billion U.S. adalimumab market, as well as our growth strategy. oncology with the combined product candidates toripalimab and PD-1. Lee’s unique healthcare knowledge and expertise will play an important role in refining our medical and commercial strategy for these products.

“With the upcoming launch of YUSIMRY™, Coherus has the potential to realize significant cost savings for patients and payers as the adalimumab market becomes more efficient,” said Dr. Newcomer. “I am confident that the company has the fundamental capabilities and product offerings necessary to achieve commercial success with YUSIMRY and its novel immuno-oncology product candidates. »

Coherus also announced today that James Healy, MD, Ph.D., a board member since 2014, has resigned from the Coherus Board of Directors. Coherus plans to retain Dr. Healy as a consultant to assist with the company’s immuno-oncology strategy.

“Dr. Healy has been a friend and valued advisor to Coherus for many years and has played a key role in shaping our company’s strategic vision. I am grateful for his years of service,” Mr. Lanfear said.

“Coherus has both the management team and the assets in place to be an emerging leader in the field of immuno-oncology, supported by revenues generated from its biosimilar products,” said Dr. Healy. “Each product in the company’s portfolio addresses patients’ needs in a unique way and could help change the course of their lives. It was a pleasure to work with Coherus and I wish the best to the management team, the board of directors, the shareholders and the patients we serve.

About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company developing a leading immuno-oncology franchise funded by cash generated from its commercial biosimilars business. In 2021, Coherus obtained a license for toripalimab, an anti-PD-1 antibody, in the United States and Canada. A Biologics License Application for toripalimab for the treatment of metastatic or recurrent nasopharyngeal carcinoma is currently under priority review by the FDA, with a target action date of April 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of lung, breast, liver, skin, kidney, stomach, esophagus and bladder cancers.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta® in the United States, and plans to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the United States in 2023. The FDA is currently reviewing Biologics License Application for CIMERLI™, formerly CHS-201, a biosimilar of Lucentis® (ranibizumab), with a target action date of August 2022. Coherus is also developing CHS-305, a biosimilar of Avastin® (bevacizumab).

Forward-looking statements
Except for historical information contained in this press release, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including including, but not limited to, statements regarding Coherus’ ability to grow its immuno-oncology franchise to achieve market leadership; ability of Coherus to generate cash; Coherus investment projects; Coherus’ expectations regarding the launch date of YUSIMRY™; expectations regarding the future commercial success of Coherus’ products and product candidates; and expectations regarding the impact of products in Coherus’ portfolio.

These forward-looking statements involve substantial risks and uncertainties that could cause the actual results, performance or achievements of Coherus to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to the COVID-19 pandemic; risks relating to our existing and potential collaboration partners; the risks of the drug development position of Coherus’ competitors; risks and uncertainties of the regulatory approval process, including the timeliness of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk of execution by Coherus of its change of strategy from a focus on biosimilars to a focus on building a leading immuno-oncology franchise; the risk that Coherus may not be able to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of potential litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the material risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business generally, see Coherus’ Annual Report on Form 10- K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021, its subsequent quarterly reports on Form 10-Q, including the sections titled “Risk Factors” and in other documents that we file with the Securities and Exchange Commission.

UDENYCA®, YUSIMRY™ and CIMERLI™, whether or not appearing in large print or with the mark symbol, are trademarks of Coherus, its affiliates, its affiliates or its licensors or joint venture partners, unless otherwise specified. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.

Contact Coherus
Investors:
McDavidStilwell
Financial director
Coherus BioSciences, Inc.
[email protected]

Media:
Cheston Turbyfill
Coherus BioSciences, Inc.
[email protected]

Previous Bee Readers Take on Single-Payer Healthcare and Take Climate Action
Next Planned 'long-term viable' uses for derelict buildings in Cork